PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

You may be eligible if

• Microscopic confirmation of a diagnosis of metastatic adenocarcinoma (pathology may be from either the primary tumor or metastatic lesion) or poorly differentiated carcinoma of the pancreas s/p 1 or 2 prior chemotherapy regimens for metastatic disease (excluding neuroendocrine tumors, periampullary tumors and cystadenocarcinoma)
• Measurable disease by RECIST criteria
• ECOG PS 0 or 1
• Life expectancy of at least 12 weeks
• Absolute neutrophil count (ANC) \>= 1,500/mm\^3
• Platelet count \>= 100,000/mm\^3
• Creatinine =\< 2.0 mg/dl
• Total bilirubin =\< 2.0 mg/dl
• AST and ALT =\< 2.5 x ULN in absence of liver metastasis; =\< 5 x ULN in presence of liver metastasis
• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of therapy
• Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation
• Ability to understand and the willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study-specific procedures
• History of stroke within 6 months of treatment or other significant neurological limitations
• History of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty of coronary bypass surgery
• History of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block
• New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea or edema that required current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or diuretics
• Current or prior radiation therapy to the left hemithorax
• Major surgery within 4 weeks prior to entering the study
• Poor venous access for study drug administration or would require a peripheral or central indwelling catheter for study drug administration; study drug administration via indwelling catheters is prohibited at this time
• Use of any investigational agents within 4 weeks prior to entering the study
• History of severe allergic reactions to excipients (e.g., Polyethylene glycol 300 and Polysorbate 80), including severe hypersensitivity reactions defined as \>= Grade 3 based on NCI CTCAE version 4.0
• Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation or systemic steroids for treatment of autoimmune disease), however, patients may receive steroids for stable CNS metastases as described in exclusion criterion 1
• Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
• Ventricular ejection fraction (Ef) =\< 55%
• Baseline QTc \> 470 msec or previous history of QT prolongation while taking other medications
• Patients who received more than two lines of prior therapy for metastatic disease, neoadjuvant or post-op adjuvant therapy is not considered one line of therapy as long as there was \> 6 months of disease-free interval
• Pregnant or breast-feeding females